The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Molecular basis for LDL receptor recognition by PCSK9
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) posttranslationally regulates hepatic low-density lipoprotein receptors (LDLRs) by binding to LDLRs on the cell surface, leading to their degradation. The binding site of PCSK9 has been localized to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR. Here, we describe the crystal structure of a complex between PCSK9 and the EGF-A domain of the LDLR. The binding site for the LDLR EGF-A domain resides on the surface of PCSK9's subtilisin-like catalytic domain containing Asp-374, a residue for which a gain-of-function mutation (Asp-374–Tyr) increases the affinity of PCSK9 toward LDLR and increases plasma LDL-cholesterol (LDL-C) levels in humans. The binding surface on PCSK9 is distant from its catalytic site, and the EGF-A domain makes no contact with either the C-terminal domain or the prodomain. Point mutations in PCSK9 that altered key residues contributing to EGF-A binding (Arg-194 and Phe-379) greatly diminished binding to the LDLR's extracellular domain. The structure of PCSK9 in complex with the LDLR EGF-A domain defines potential therapeutic target sites for blocking agents that could interfere with this interaction in vivo , thereby increasing LDLR function and reducing plasma LDL-C levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PCSK9 consists of a pro-domain, catalytic and C-terminal domains and is secreted as a complex containing the cleaved pro-domain non-covalently bound to the mature form.
“PCSK9 consists of a pro-domain, catalytic and C-terminal domains and is secreted as a complex containing the cleaved pro-domain non-covalently bound to the mature form.15”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [15]
Upon intracellular processing, PCSK9 is secreted from hepatocytes where it binds extracellularly to the EGF-A domain of LDLR leading to its lysosomal degradation.
“Upon intracellular processing, PCSK9 is secreted from hepatocytes where it binds extracellularly to the epidermal growth factor-A (EGF-A) domain of LDLR leading to its lysosomal degradation.14,15”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [15]
PCSK9 binds through the catalytic domain to the EGF-A of LDLR on the cell surface in hepatocytes.
“PCSK9 binds through the catalytic domain to the epidermal growth factor-like repeat (EGF-A) of LDLR on the cell surface in hepatocytes.14,15”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477
Davis, C. G., Goldstein, J. L., Südhof, T. C., Anderson, R. G. W., Russell, D. W., & Brown, M. S. (1987) · Nature · doi:10.1038/326760a0 · Cited by 411
Flagged first, then by citations
Research works printed but not linked: 37
- 10.1016/j.tibs.2006.12.008 · DOI · Paper page
- 10.1097/MOL.0b013e3281338531 · DOI
- 10.1038/ng1161 · DOI · Paper page
- 10.1016/j.jmb.2004.10.050 · DOI
- 10.1074/jbc.M108740200 · DOI
- 10.1016/0955-0674(93)90078-5 · DOI
- 10.1042/bj3270625 · DOI
- 10.1074/jbc.M409699200 · DOI · Paper page
- 10.1172/JCI29383 · DOI · Paper page
- 10.1038/nsmb1235 · DOI · Paper page
- 10.1073/pnas.0703402104 · DOI
- 10.1016/j.str.2007.04.004 · DOI · Paper page
- 10.1074/jbc.M701634200 · DOI · Paper page
- 10.1074/jbc.M702027200 · DOI · Paper page
- 10.1074/jbc.C700095200 · DOI · Paper page
- 10.1042/BJ20070664 · DOI
- 10.1016/0092-8674(84)90388-X · DOI · Paper page
- 10.1016/j.sbi.2003.10.001 · DOI
- 10.1126/science.1078124 · DOI · Paper page
- 10.1002/humu.1380010602 · DOI · Paper page
- 10.1042/bj2770677 · DOI
- 10.1016/S0969-2126(01)00606-2 · DOI
- 10.1006/jmbi.2001.4867 · DOI
- 10.1016/j.molcel.2004.09.038 · DOI
- 10.1016/j.tibs.2005.03.007 · DOI · Paper page
- 10.1111/j.1600-0854.2007.00562.x · DOI · Paper page
- 10.1016/0092-8674(95)90059-4 · DOI
- 10.1074/jbc.M305175200 · DOI
- 10.1074/jbc.M410077200 · DOI · Paper page
- 10.1074/jbc.M606495200 · DOI · Paper page
- 10.1086/507488 · DOI
- 10.1073/pnas.93.21.11487 · DOI
- 10.1016/S0076-6879(97)76066-X · DOI · Paper page
- 10.1107/S0907444994003112 · DOI
- 10.1107/S0907444903028956 · DOI
- 10.1107/S0907444998003254 · DOI
- 10.1107/S0907444996012255 · DOI
Cited by
Sorted by citations
Mechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Self-citationFeedback Regulation of Cholesterol Uptake by the LXR–IDOL–LDLR Axis
Zhang, L., Reue, K., Fong, L. G., Young, S. G., & Tontonoz, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.250571 · Cited by 137
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131
Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113035 · Cited by 107
Abifadel, M., Rabès, J.-P., Jambart, S., Halaby, G., Gannagé-Yared, M.-H., Sarkis, A., Beaino, G., Varret, M., Salem, N., Corbani, S., et al. (2009) · Human Mutation · doi:10.1002/humu.21002 · Cited by 99
Duff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Liu, M., Wu, G., Baysarowich, J., Kavana, M., Addona, G. H., Bierilo, K. K., Mudgett, J. S., Pavlovic, G., Sitlani, A., Renger, J. J., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006635 · Cited by 98
Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88
PCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
Strøm, T. B., Tveten, K., & Leren, T. P. (2014) · Biochemical Journal · doi:10.1042/bj20130930 · Cited by 48
Gibbs, J. P., Doshi, S., Kuchimanchi, M., Grover, A., Emery, M. G., Dodds, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Blom, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.840 · Cited by 42
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
Poznyak, A. V., Sukhorukov, V. N., Eremin, I. I., Nadelyaeva, I. I., Gutyrchik, N. A., & Orekhov, A. N. (2023) · Biomedicines · doi:10.3390/biomedicines11020503 · Cited by 8
“PCSK9 is responsible for the degradation of both LDLR and structurally similar receptors, such as VLDLR and ApoER2, since all these receptors include an epidermal growth factor-like repeat A (EGF-A) domain which PCSK9 binds to and targets the complex for lysosomal degradation [21].”
BackgroundVelagapudi, S., Miranda, M. X., Adla, P., Kraler, S., Mohammed, S. A., Baki, S., Robert, J., Rohrer, L., Lee, H., Jang, H.-D., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf087 · Cited by 4
Metadata
- Authors
- Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., & Deisenhofer, J.
- Affiliations
- Departments of *Biochemistry,
- Molecular Genetics, and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-02-12
- Volume
- 105
- Issue
- 6
- Pages
- 1820-1825
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 389
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review